The transcriptomic profile of CD138+ cells from patients with early progression from smoldering to active multiple myeloma remains substantially unchanged

摘要

Smoldering myeloma (SMM) is a pre-malignant monoclonal gammopathy with an annual risk of about 10% of progressing to active multiple myeloma (MM).1 The International Myeloma Working Group (IMWG) has recently updated the diagnostic criteria for SMM.2 The previously defined “ultra high-risk” SMM (characterized by specific biomarkers associated with a greater than 80% risk of progression to symptomatic MM within 2 years) has now been incorporated in active MM. SMM is biologically heterogeneous and encompasses a condition with a very low rate of progression to symptomatic MM, behaving similarly to monoclonal gammopathy of uncertain significance, as well as a disease with acquired organ damage and progression to active MM within 5 years from diagnosis.